1 |
Campbell AJ, Buchner DM. For debate: unstable disability and the fluctuations of frailty[J]. Age Ageing, 1997, 26(4): 315-318.
|
2 |
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3): M146-M156.
|
3 |
Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging[J]. ScientificWorldJournal, 2001, 1: 323-336.
|
4 |
Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review[J]. Eur J Intern Med, 2016, 31: 3-10.
|
5 |
Clegg A, Young J, Iliffe S, et al. Frailty in elderly people[J]. Lancet, 2013, 381(9868): 752-762.
|
6 |
Xia CQ, Xie HY, Huang YH, et al. Spatiotemporal gait characteristics during single- and dual-task walking are associated with the burden of cerebral small vessel disease[J]. Front Neurol, 2023, 14: 1285947.
|
7 |
Duering M, Biessels GJ, Wardlaw JM. Neuroimaging standards for research into small vessel disease-advances since 2013[J]. Lancet Neurol, 2023, 22(7): 602-618.
|
8 |
Kant IMJ, Mutsaerts HJMM, van Montfort SJT, et al. The association between frailty and MRI features of cerebral small vessel disease[J]. Sci Rep, 2019, 9(1): 11343.
|
9 |
Kelaiditi E, Cesari M, Canevelli M, et al. Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group[J]. J Nutr Health Aging, 2013, 17(9): 726-734.
|
10 |
Sargent L, Nalls M, Amella EJ, et al. Shared mechanisms for cognitive impairment and physical frailty: a model for complex systems[J]. Alzheimers Dement (N Y), 2020, 6(1): e12027.
|
11 |
Ruan Q, Yu Z, Chen M, et al. Cognitive frailty, a novel target for the prevention of elderly dependency[J]. Ageing Res Rev, 2015, 20: 1-10.
|
12 |
Chen LK, Arai H. Physio-cognitive decline as the accelerated aging phenotype[J]. Arch GerontolGeriatr, 2020, 88: 104051.
|
13 |
Sugimoto T, Sakurai T, Ono R, et al. Epidemiological and clinical significance of cognitive frailty: a mini review[J]. Ageing Res Rev, 2018, 44: 1-7.
|
14 |
Carini G, Musazzi L, Bolzetta F, et al. The potential role of miRNAs in cognitive frailty[J]. Front Aging Neurosci, 2021, 13: 763110.
|
15 |
Ipson BR, Fletcher MB, Espinoza SE, et al. Identifying exosome-derived microRNAs as candidate biomarkers of frailty[J]. J Frailty Aging, 2018, 7(2): 100-103.
|
16 |
Rusanova I, Diaz-Casado ME, Fernández-Ortiz M, et al. Analysis of plasma microRNAs as predictors and biomarkers of aging and frailty in humans[J]. Oxid Med Cell Longev, 2018, 2018: 7671850.
|
17 |
Xia X, Wang Y, Zheng JC. The microRNA-17 ~ 92 family as a key regulator of neurogenesis and potential regenerative therapeutics of neurological disorders[J]. Stem Cell Rev Rep, 2022, 18(2): 401-411.
|
18 |
Kim BS, Jung JY, Jeon JY, et al. Circulating hsa-miR-30e-5p, hsa-miR-92a-3p, and hsa-miR-223-3p may be novel biomarkers in systemic lupus erythematosus[J]. HLA, 2016, 88(4): 187-193.
|
19 |
Joilin G, Gray E, Thompson AG, et al. Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis[J]. Brain Commun, 2020, 2(1): fcaa053.
|
20 |
He JR, Zhang Y, Lu WJ, et al. Age-related frontal periventricular white matter hyperintensities and miR-92a-3p are associated with early-onset post-stroke depression[J]. Front Aging Neurosci, 2017, 9: 328.
|
21 |
Shi Y, Yi Z, Zhao P, et al. MicroRNA-532-5p protects against cerebral ischemia-reperfusion injury by directly targeting CXCL1[J]. Aging (Albany NY), 2021, 13(8): 11528-11541.
|
22 |
Mu J, Cheng X, Zhong S, et al. Neuroprotective effects of miR-532-5p against ischemic stroke[J]. Metab Brain Dis, 2020, 35(5): 753-763.
|
23 |
Mu L, Jiang L, Chen J, et al. Serum inflammatory factors and oxidative stress factors are associated with increased risk of frailty and cognitive frailty in patients with cerebral small vessel disease[J]. Front Neurol, 2022, 12: 786277.
|
24 |
Siejka TP, Srikanth VK, Hubbard RE, et al. Frailty and cerebral small vessel disease: a cross-sectional analysis of the tasmanian study of cognition and gait (TASCOG)[J]. J Gerontol A Biol Sci Med Sci, 2018, 73(2): 255-260.
|
25 |
Siejka TP, Srikanth VK, Hubbard RE, et al. White matter hyperintensities and the progression of frailty-the tasmanian study of cognition and gait[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(8): 1545-1550.
|
26 |
Kant IMJ, Mutsaerts HJMM, van Montfort SJT, et al. The association between frailty and MRI features of cerebral small vessel disease[J]. Sci Rep, 2019, 9(1): 11343.
|
27 |
Sugimoto T, Ono R, Kimura A, et al. Cross-sectional association between cognitive frailty and white matter hyperintensity among memory clinic patients[J]. J Alzheimers Dis, 2019, 72(2): 605-612.
|
28 |
Yoshiura K, Fukuhara R, Ishikawa T, et al. Brain structural alterations and clinical features of cognitive frailty in Japanese community-dwelling older adults: the Arao study (JPSC-AD)[J]. Sci Rep, 2022, 12(1): 8202.
|
29 |
Zhào H, Wei W, Huang YH, et al. Cognitive frailty among elderly chinese patients with cerebral small vessel disease: a structural MRI study[J]. Front Med (Lausanne), 2020, 7: 397.
|
30 |
Liu Z, Hsu FC, Trombetti A, et al. Effect of 24-month physical activity on cognitive frailty and the role of inflammation: the LIFE randomized clinical trial[J]. BMC Med, 2018, 16(1): 185.
|
31 |
Yoon DH, Lee JY, Song W. Effects of resistance exercise training on cognitive function and physical performance in cognitive frailty: a randomized controlled trial[J]. J Nutr Health Aging, 2018, 22(8): 944-951.
|
32 |
Lv X, Niu H. Mesenchymal stem cell transplantation for the treatment of cognitive frailty[J]. J Nutr Health Aging, 2021, 25(6): 795-801.
|
33 |
Scassellati C, Ciani M, Galoforo AC, et al. Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment[J]. Mech Ageing Dev, 2020, 186: 111210.
|
34 |
Ruan Q, Ruan J, Zhang W, et al. Targeting NAD+ degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty[J]. Pharmacol Res, 2018, 128: 345-358.
|